TY - JOUR
T1 - Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma
T2 - results from the phase 2 ELARA trial
AU - Fukuhara, Noriko
AU - Kato, Koji
AU - Goto, Hideki
AU - Takeshi, Tajima
AU - Kawaguchi, Mayu
AU - Tokushige, Kota
AU - Akashi, Koichi
AU - Teshima, Takanori
AU - Harigae, Hideo
AU - Schuster, Stephen J.
AU - Thieblemont, Catherine
AU - Dreyling, Martin
AU - Fowler, Nathan
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2023/2
Y1 - 2023/2
N2 - Background: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from ELARA. Methods: ELARA (NCT03568461) is a global single-arm trial of tisagenlecleucel in patients with r/r FL who received ≥ 2 prior lines of therapy. The primary endpoint was the complete response rate (CRR), and the secondary endpoints were the overall response rate, duration of response, progression-free survival, overall survival, safety, and cellular kinetics. Results: As of March 29, 2021, nine Japanese patients were enrolled and received tisagenlecleucel with a median follow-up of 13.6 months (range, 10.5‒19.3). Per independent review committee, CRR was 100% (95% CI 63.1‒100). Within 8 weeks of infusion, cytokine release syndrome (CRS) of any grade was reported in 6 patients (66.7%); however, no grade ≥ 3 CRS or any grade serious neurological events or treatment-related deaths were observed. Conclusion: Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.
AB - Background: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from ELARA. Methods: ELARA (NCT03568461) is a global single-arm trial of tisagenlecleucel in patients with r/r FL who received ≥ 2 prior lines of therapy. The primary endpoint was the complete response rate (CRR), and the secondary endpoints were the overall response rate, duration of response, progression-free survival, overall survival, safety, and cellular kinetics. Results: As of March 29, 2021, nine Japanese patients were enrolled and received tisagenlecleucel with a median follow-up of 13.6 months (range, 10.5‒19.3). Per independent review committee, CRR was 100% (95% CI 63.1‒100). Within 8 weeks of infusion, cytokine release syndrome (CRS) of any grade was reported in 6 patients (66.7%); however, no grade ≥ 3 CRS or any grade serious neurological events or treatment-related deaths were observed. Conclusion: Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.
KW - CAR-T
KW - ELARA
KW - Relapsed or refractory follicular lymphoma
KW - Tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85142274471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142274471&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03481-y
DO - 10.1007/s12185-022-03481-y
M3 - Article
C2 - 36404384
AN - SCOPUS:85142274471
SN - 0925-5710
VL - 117
SP - 251
EP - 259
JO - International journal of hematology
JF - International journal of hematology
IS - 2
ER -